Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Checkpoint Therapeutics Q2 EPS $(0.18) Beats $(0.30) Estimate, Sales $41.00K Beat $20.00K Estimate

Author: Benzinga Newsdesk | August 12, 2024 08:44am
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.30) by 40 percent. This is a 82.86 percent increase over losses of $(1.05) per share from the same period last year. The company reported quarterly sales of $41.00 thousand which beat the analyst consensus estimate of $20.00 thousand by 105.00 percent. This is a 32.26 percent increase over sales of $31.00 thousand the same period last year.

Posted In: CKPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist